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INTRODUCTION 
Ionic homeostasis is a pivotal process in the regulation of cell metabolism, in 
particular for excitable cells such as neurons. Alterations of ionic balance are 
common in different pathologic conditions, such as brain ischemia or epilepsy. 
For instance, modifications in cytosolic and subcellular calcium ions (Ca2+) 
dynamics have been indicated as main pathways underlying ischemic neuronal 
death; moreover, Na+, K+ and Cl- imbalances seem to play an important role in 
regulating cell survival. Indeed, ion channels - apart from their well-known role 
in determining neuronal firing- can regulate different cellular proteins and 
processes, such as kinases, transcription factors, mitochondrial function and 
free radical formation (Arumugan et al., 2009). Among the different ion species, 
potassium (K+) seems to play a primary role in the regulation of neuronal cell 
death/survival. Indeed, growing evidence demonstrate that low intracellular K+ 
concentrations ([K+]i) lead to apoptosis in neurons, either with an indirect- (Cl- 
and water outflow, cell shrinkage, mitochondrial swelling and subsequent 
induction of pro-apoptotic signals) or with a direct- mechanism (activation of 
nucleases and caspases, normally inhibited by high [K+]i  levels) (Leung, 2010). 
[K+]i are strictly regulated by different classes of both voltage-dependent and -
independent K+ channels; therefore, modulation of the activity of such relevant 
class of membrane proteins can  affect cell fate. Indeed, pharmacological 
blockade of K+ channels (induced by exposure to drugs such as 
tetraethylammonium, TEA), or reduction of the driving force for K+ (obtained by 
an increase of [K+]e) lead to a decrease in [K+]i outflow from the cell and to a 
reduction of neuronal death in different in vitro models of neuronal damage, 
such as serum deprivation (Yu et al., 1997) or toxic -amyloid fragments 
exposure (Colom et al., 1998). An increased expression or activity of different 
classes of K+ channels seems to be an early event in several in vitro models of 
neurotoxicity (Pannaccione et al., 2005 and 2007). On the other hand, it should 
be mentioned that a decreased expression/function of some subclasses of K+ 
channels causes neuronal hyper-excitability, thus promoting apoptotic neuronal 
death (Henshall and Simon, 2005). In this view, K+ channels-activating drugs, by 
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reducing neuronal excitability and subsequent energy loss, might represent a 
useful tool to prevent neuronal cell death.  
This dual role exerted by K+ in neuronal survival might depend on the 
differential function of distinct classes of voltage-dependent K+ channels, each 
showing peculiar subcellular location, biophysical properties, modulation by 
second messengers, and pharmacological profile (Leung et al., 2010). 
 
Potassium channels classification 
Potassium channels are a heterogeneous and ubiquitous family of proteins, 
encoded by more than 78 genes in human (Wulff et al., 2009). They are 
transmembrane proteins able to selectively conduct K+ ions across the 
phospholipidic bilayer with a very high flow rate (106-108/ions/s), in a 
direction determined by the electrochemical gradient (driving force). Such 
specific and fast process is made possible by particular features of these 
proteins, namely: 1) a pore with a selectivity filter, that allow only K+ ions to 
flow across the cell membrane; 2) a gating mechanism, allowing the channel to 
open or close; the stimulus determining the gating can be various (ligand-
binding, changes in membrane potential, variations in intracellular Ca2+ 
concentrations) but usually specific for each channel.  
Since the reversal potential for K+ is more negative than cell membrane resting 
potential, K+ ions flow is commonly outward; thus, K+ channels cause a re- or a 
hyper-polarization of the cell, thus stabilizing membrane potential and reducing 
cell excitability. 
The first gene encoding for a K+ channel was cloned in 1987 from a Drosophila 
mutant called Shaker, because of the fruit fly characteristic behavior under 
ether anesthesia (Papazian et al., 1987). Other three members of K+ channel 
family (called Shab, Shaw and Shal) were cloned from the same genome, 
opening the door to the subsequent cloning of more than 200 genes in different 
species encoding for K+ channels. Based on the aminoacidic sequence and on 
gating properties, K+ channels are usually classified in three subfamily:  
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 Inward rectifier K+ channels with one pore and two transmembrane 
domains (Kir): these channels are formed by two transmembrane 
domains and a pore loop between, that usually assemble in tetramers, 
although more complex arrangements have been described (Shieh et al., 
2000). Members of this family are called inward rectifier because of their 
ability to conduct current mainly in the inward direction, thus 
contributing in setting membrane resting potential. This property is 
attributed to gating mechanisms in which internal Mg2+ and polyamines 
occlude access of K+ ions to the inner part of the pore (Matsuda, 1991; 
Ficker et al., 1994). The pathophysiological relevance of these channels is 
underlined by diseases caused by mutations in the genes encoding for 
members of Kir family. For instance, mutations in Kir1.1 (KCNJ1 o ROMK) 
are responsible for Bartter Syndrome (Simon et al., 1996), characterized 
by salt wasting from the renal tubules, mainly the thick ascending loop of 
Henle. Moreover, alteration in kcnj2 are linked in 60% of cases to 
Andersen-Tawil Syndrome, a disorder that causes periodic paralysis, 
arrhythmia and  developmental abnormalities (Bendahhou et al, 2005), 
while kcnj11 gene defects are associated to congenital hyperinsulinism 
and permanent neonatal diabetes mellitus (Bennett et al., 2010). 
 K+ channels containing four transmembranes with two pore regions (K2P). 
The first member of this family to be identified in mammals was called 
TWIK1 (Tandem of P-domains in a Weak Inward Rectifying K channel); 
as other channels of this family, K2P do assemble in dimers and are 
commonly regulated by various stimuli, such as mechanical stress and 
arachidonic acid KCNK2, KCNK4 and KCNK10), protein kinase C and low 
pH (KCNK1 and KCNK6) or hypoxia (KCNK3 and KCNK9). Moreover, K2P 
channels in central nervous system are activated by volatile anesthetics 
like halothane, thus contributing to neurons “silencing” (Gruss et al, 
2004). Although no disease-causing mutation has been found in genes 
encoding for these channels, it has been suggested that members 
belonging to K2P group participate in the regulation of different 
pathophysiologic processes such as electrolytes transport in the kidney, 
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general anesthesia, pain, main depression and neuroprotection 
(Heitzmann e Warth, 2008). 
  Voltage-gated K+ channels containing six (Shaker-like, Kv) or seven (Slo-
like, KCa) transmembrane domains with one pore. This group comprises K+ 
channels activated by membrane depolarization, divided in 12 sub-
families by sequence homology criteria and named Kv1- Kv12 (Gutman et 
al., 2005). They are formed by six transmembrane domains (called S1-
S6), with segment S1-S4 forming the voltage-sensing domain (VSD) and 
the S5-S6 region making up the pore. Among them, Kv1- Kv4 are the 
typical voltage-gated K+ channel, showing high similarity to their 
orthologous in Drosophila (Shaker, Shab, Shaw, Shal, respectively); 
subsequent genomic studies led to the cloning of the other eight 
subfamily, some of them strictly related to their own orthologous 
channel in Drosophila, such as Kv7 (KCNQ), Kv10 (Eag) Kv11 (Erg), Kv12 
(Elk). Kv5, Kv6, Kv8 e Kv9 families do not underlie any K+ conductance, but 
they do regulate the expression and the biophysical properties of other 
subunits they are assembled with. KCa channels are slightly different 
from the other members of this group, since they have an additional 
transmembrane segment (called S0) and channel gating regulated also 
by intracellular calcium levels; this ability is due to a C-terminal 
cytoplasmic domain able to sense calcium levels (named calcium bowl) 
in high conductance channels (BK), or to the strict interaction with 
calmodulin (intermediate or small conductance channels, IK/SK; Fanger 
et al, 1999).  
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As for other ion channels, main pore-forming K+ channels subunits (called  
subunit) can be assembled to accessory subunits which can regulate their 
activity, subcellular localization and interaction with other proteins and cellular 
 
 
Figure 1. Potassium channels classification. 
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structure, such as cytoskeleton or extracellular matrix (Isom et al., 1994). For 
instance, KchAP regulates the expression and function of Kv2.1, Kv1.3 and Kv4.3 
(Kuryshev et al, 2000), while different  subunits can modulate the activity and 
toxin-sensitivity of BKCa channels (Brenner et al., 2000); moreover, sulfonylurea 
receptor (SUR) confers nucleotide sensitivity to inward rectifier Kir6.1 e Kir6.2 
(Aguilar-Bryan et al, 1995), whereas minK subunit modifies biophysical 
properties of Kv7.1 (Sanguinetti et al, 1996).   
Finally, phosphorylation, ubiquitinylation, palmoitolylation or interaction with 
membrane lipids are further mechanisms by which K+ channels activity can be 
modulated. 
 
Voltage-gated K+ channels containing six transmembrane domains with 
one pore 
The study of the structure of K+ channels has given a great contribution to the 
understanding of the mechanisms underlying the functioning of voltage-gated 
ion channels. In particular, X-ray crystallography studies on procariotic and 
mammalian K+ channels have clarified the molecular features that determine the 
selectivity filter, the VSD, 
and the conformational 
changes that mediate the 
channel gating (MacKinnon, 
2004). In particular, in 
these studies the pore has 
been individuated in a 
hydrophobic aminoacids-
rich cavity of about 10 Å-
diameter, followed by a 12 
Å-long region, that 
represent the selectivity 
filter; in the latter region, a conserved aminoacid motif (TVGYG) is present. 
According to this model, the hydrophobic region pushes hydrated K+ ions to the 
selectivity filter, where the aminoacids of the conserved motif substitute water 
molecules in the interaction with K+ ions, thus permitting the rapid flow of the 
 
Figure 2. Molecular structure of procariotic KcsA 
potassium channel. The interaction of K+ ions (in green) 
with aminoacidic sequence T-V-G-Y-G is also shown 
(modified from Lockless et al, 2007. PLoS Biol 
5(5):e121). 
 
 
9 
 
cations along the cavity (Long et al, 2005 a-b). X-ray crystallography has also 
clarified the conformational changes occurring in the VSD, whose function had 
been investigated in many studies by using different techniques (“gating” 
current measurements, Armstrong and Bezanilla, 1974; mutagenesis studies, 
Papazian et al, 1991, Perozo et al, 1994; fluorescence studies, Mannuzzu et al, 
1996, Cha and Bezanilla, 1997). In these studies, S4 segment was indicated as 
the main determinant of voltage-sensitivity, due to the presence of several 
positively-charged aminoacids (lysine or arginine), able to sense the variations 
in membrane potential and trigger the conformational changes of the protein 
leading to channel opening. Positively-charged aminoacid in S4 segment can 
interact with different negatively-charged residues in the S1-S3 region; these 
interactions seem to be very important for both channel stabilization and gating 
charge movements (Miceli et al., 2011). Movements of S4 segment are supposed 
to be translated to pore opening through a mechanism involving S4–S5 linker. 
Indeed, it has been proposed that, upon membrane depolarization, S4 outward 
movement, by pulling onto the S4–S5 linker, causes the bending of the S6 gating 
hinge to open the S6 intracellular helix bundle, leading to pore opening (Long et 
al., 2005a and b). However, the exact rearrangements occurring in the VSD are 
not fully understood, and at least three different models have been proposed 
(Miceli et al., 2011): 
 The helical screw or sliding helix model propose that, when the membrane 
is depolarized, the S4 helix rotates along its length and translate along its 
axis, thus moving outwardly by a length corresponding to about three α-
helical turns. The outward movement involves the sequential interaction 
between positively-charged and negatively-charged residues during VSD 
activation.  
 The transporter model suggests that, during activation S4 would mainly 
undergo rotational movements without significant translational 
movements; upon membrane depolarization, arginines in the S4 segment 
would move from a crevice in contact with the intracellular solution into 
another crevice in contact with the extracellular solution. The resting 
and activated positions of the VSD would be stabilized by ionized 
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hydrogen bonds between the S4 arginines and two negatively charged 
clusters located in the S1, S2 and S3 helices. 
 The paddle model proposes that S4 and part of S3 form a helical hairpin, 
or paddle, that freely moves by a large extent (15–20 Å) across the lipidic 
bilayer during each gating cycle; this large movement would be 
transmitted to the pore region through the S4-S5 linker, thus causing the 
pore opening. However, paddle model seems to be incompatible with 
several experimental evidence obtained in other Kv; since this model is 
mainly based on the crystal structure of the bacterial channel KvAP 
(Jiang et al., 2003a and b) it has been proposed that this model is based 
on a non native state of the channel caused by artifacts of the 
crystallization procedure (Catterall, 2010).    
As stated before, voltage-gated K+ channels are formed by six hydrophobic 
segments spanning the membrane, named S1-S6. The pore region is formed by 
S5-S6 domains, while S1-S4 segments represent voltage-sensing domain (VSD).  
Functional K+ channels are formed by the assembly of four -subunits, both in 
homomeric or in heteromeric configuration. Protein region responsible for 
tetramerization are located in the N-terminus (Kv1, Li et al., 1992; Shaker, Shao 
and Papazian, 1993) or in the C-terminus (Kv10, Kv11 e Kv7; Ludwig et al, 1997; 
Kupershmidt et al, 1998; Schwake et al, 2000) of -subunits. 
 
The Kv7 channel family 
The family of voltage-dependent Kv7 (KCNQ) K+ channel comprises five 
members, namely Kv7.1-Kv7.5, each showing a distinct tissue distribution 
(Soldovieri et al., 2011). As other Kv channels, Kv7 channels are composed by six 
transmembrane domains (named S1-S6), a short N-terminal and a longer C-
terminus, both located in the cytoplasmic side. Channel pore is formed by S5-S6 
domains, while transmembrane regions S1-S4 constitute the voltage sensing 
domain (VSD), which allows channel gating in response to changes in 
membrane potential. In particular, S4 segment contains from four to six 
positively charged arginines separated by two to three uncharged residues; 
unlike other Kv channels, the third R is replaced by a neutral glutamine residue. 
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The long C-terminus is a typical feature of Kv7 channels and it is organized in 
four   helices (named A-D) containing different sites responsible for 
heteromeric and homomeric assembly, interaction with regulatory molecules, 
subcellular localization, and binding of accessory proteins (Haitin e Attali, 
2008). Among them we can recognize: 
 Calmodulin. The regulatory protein calmodulin (CaM) seems to be 
constitutively bound to the COOH-terminal region of Kv7.2/3 channels, 
irrespective of the intracellular Ca2+ concentration ([Ca2]i), in particular 
to two sequences in helices A and B. Calmodulin effects on Kv7 channel 
have not been elucidated yet. In general, CaM is believed to play a key 
role for Kv7 channel folding and trafficking (Wen e Levitan, 2002; Yus-
Najera et al, 2002; Gamper e Shapiro, 2003), but also in regulating Kv7 
currents in response to changes in intracellular Ca2+ levels. 
 Syntaxin 1A. Helix-A seems to mediate Kv7.2 channel interaction with the 
plasma membrane protein syntaxin 1A, thus addressing this subunit to 
pre-synaptic sites in neurons (Regev  et al., 2009) 
 Phosphatidylinositol-(4,5)-Bisphosphate (PIP2). This lipid seems to 
stabilize the open state of Kv7 channels (Delmas and Brown, 2005). 
Indeed, differences in the single channel open probability among Kv7 
channels subunits appear to be dependent on their intrinsic affinities for 
intracellular PIP2 (Li et al., 2005). The binding site for PIP2 is still 
unknown, although recent evidence suggest as possible binding site a 
region between helices A and B (Hernandez et al., 2009). 
 Kinases. C-terminal region contains phosphorylation sites for different 
kinases such as PKA and PKC, which interact with anchoring protein 
AKAP 79/150 in a trimeric complex (Hoshi et al, 2003); in addition, 
tyrosin-kinase Src (Gamper et al, 2003) can suppress channel activity. 
Putative phosphrylation sites have been individuated for other protein 
such as EGF (Jia et al, 2007).  
 Ankyrin G. An interaction domain for the adaptor protein Ankyrin-G has 
been identified in Kv7.2 and Kv7.3, but not for other Kv7 subunits. This 
“adaptor” protein mediate heteromeric Kv7.2/3 channels localization at 
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the axonal initial segment and Ranvier nodes (Pan et al, 2006; 
Rasmussen et al, 2007). 
 Subunit Interaction Domain. Multimerization domains and subunit-
specific heteromerization have been identified in the helices C and D 
(Schwake et al., 2003). In particular, a coiled-coil structure composed by 
the assembly of four parallel helices has been identified in Kv7.4 subunit 
by crystallography studies (Howard et al., 2007). However, additional 
sites for multimerization have been suggested for other region of the 
protein (Lundby et al., 2010).  
 Nedd4–2. A binding motif for the ubiquitin-protein ligase Nedd4–2 has 
been found in C-terminal of Kv7.1. Nedd4-2 negatively regulates currents 
elicited by Kv7.2/3, Kv7.3/5 channels and Kv7.1/KCNE1 heteromultimers, 
possibly by promoting internalization and degradation of these complex 
(Jespersen et al., 2005; Ekberg et al., 2007). 
 
Figure 3. Schematic representation of C-terminal region of Kv7 subunits (From Soldovieri et al., 
2011) 
 
As stated before, each Kv7 subunit shows a distinct tissutal expression pattern. 
A first distinction can be made between Kv7.1, that is mainly expressed in the 
heart (but also in epithelia and inner ear) and do not associate with other 
members of the family, and Kv7.2- Kv7.5, that are often referred to as “neural” 
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Kv7 channels, for their wide distribution in the nervous system (Brown and 
Passmore, 2009). In particular, Kv7.2 and Kv7.3 (often in heteromeric 
conformation) are expressed in both peripheral and central neurons, Kv7.4 is 
present in the inner ear and in neurons of acoustic pathway, while Kv7.5 is 
expressed in several brain regions and in sympathetic ganglia. Nevertheless, 
more recent evidence have demonstrated that Kv7 channels are expressed in 
many other tissues, such as visceral and vascular smooth muscle (Jepps et al., 
2013), and skeletal muscle (Iannotti et al., 2010), where they regulate muscular 
tone and differentiation/response to injury, respectively. 
 
Figure 4. Tissutal distribution of Kv7 subunits (from Soldovieri et al., 2011) 
 
Kv7 channels underlie K+ conductances which repolarize cells, thus reducing 
excitability. In particular, cardiac Kv7.1 subunits, in association with KCNEs 
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subunits, mediates an important  K+ current, called IKS that is a major component 
of the delayed rectifier current activated in the repolarization phase of cardiac 
cylce (Sanguinetti et al., 1996). By contrast, “neural” Kv7 channels do assembly 
in homo- or hetero-tetramers to underlie M-current (IKM: Brown and Adams, 
1980), a repolarizing current that reduce neuronal excitability especially after 
prolonged stimuli; this phenomenon is known as “spike frequency adaptation”. 
M-current is regulated by several Gq/11-coupled receptors such as muscarinic 
receptors (hence its name), but also adrenergic-, angiotensin II-, substance P- 
and bradykynin- receptor. Activation of these receptors does suppress IKM 
mainly by PLC-mediated reduction of PIP2 levels, which stabilize open 
conformation of the channel. Physiological relevance of M-current has been 
demonstrated at a somato-dendritic and axonal level, where it participates in 
the integration of post-synaptic inputs (Cooper et al, 2001), as well as at 
Ranvier’s node (Devaux et al, 2004). Moreover, M-current is expressed also pre-
sinaptically, where it modulates neurotransmitters release (Martire et al., 
2004). Given their relevance in regulating such delicate processes, genetic 
alteration of Kv7 subunits are often associated to inherited diseases. 
 
Kv7 subunits and genetic diseases 
Kv7.1. kcnq1 gene, encoding for Kv7.1 subunit was cloned in 1996 (Wang et al 
1996), as associated to Long QT Syndrome (LQTS), a pathologic condition 
characterized by a longer QT interval at the electrocardiogram (ECG) and thus 
predisposing to severe and possibly lethal arryhitmias such as torsades de 
pointes and consequent ventricular fibrillation. Several mutations have been 
found in kcnq1 gene, most of them impairing protein trafficking, interaction 
with regulatory molecules such as PIP2, or channel function (loss of function 
mutations). Such genetic alterations can be inherited as dominant (Romano-
Ward syndrome) or in recessive form (Jervell and Lange-Nielsen syndrome); in 
the latter case, given the expression of Kv7.1 in the inner ear, bilateral deafness 
accompanies the severe cardiac dysfunction. Interestingly, also mutations 
enhancing the activity of Kv7.1 channel (gain of function alterations) have been 
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found; they are responsible of short QT syndrome, characterized by ECG T-wave 
alterations, increased risk of atrial fibrillation and sudden infantile or adult 
death syndrome (SIDS/SADS) (Hedley et al, 2009).  
Kv7.1 has gained attention as a possible antiarrhythmic pharmacological target; 
moreover, given its expression in gastrointestinal epithelia, drugs modulating 
Kv7.1-mediated currents might be interesting tools in the treatment of fluid 
transport dysfunction.   
Kv7.2 and Kv7.3. Genes encoding for Kv7.2 and Kv7.3 (named kcnq2 and kcnq3) 
have been cloned in 1998 because of their association to a rare hereditary 
epilepsy of the newborn, called Benign Familial Neonatal Seizures (BFNS) 
(Singh et al, 1998; Charlier et al, 1998; Bievert et al, 1998). Kv7.2 and Kv7.3 show 
a distribution largely overlapping in different areas of the central nervous 
system, as well as in peripheral neurons. More recently, their expression has 
been detected also in the cochlea, in the spiral ganglion and in sensory neurons 
of the carotid body. Kv7.2 and Kv7.3 are the main molecular determinants of M-
current (IKM), a slowly activating/deactivating and non-inactivating repolarizing 
current that can be suppressed by the activation of muscarinic receptors. BFNS-
causing mutations hit more often kcnq2 gene than kcnq3 (10:1 ratio); while 
known Kv7.3 mutations are missense, Kv7.2 mutations are various, such as 
truncations, splice site defects, missense, non-sense, frame-shift mutations, as 
well as sub-microscopic deletions or duplications; moreover, many of them 
impair C-terminal region of the protein (Soldovieri et al., 2011). More recently, 
mutations in kcnq2 have been associated to other neurological disorders, such 
as Peripheral Nerve Hyperexcitability (Dedek et al, 2001; Wuttke et al, 2007). 
Kv7.4. The product of kcnq4 gene is distributed in the inner ear and in neurons 
of acoustic pathway; expression in other brain areas seems to be low, although 
it has been recently demonstrated its presence on dopaminergic neurons of 
meso-limbic and nigro-striatal pathway (Hansen et al., 2006). Moreover, Kv7.4 is 
highly expressed in non-neuronal tissues, in particular in smooth and skeletal 
muscle, and variations in its levels seem to be correlated to pathophysiological 
processes such as hypertension and differentiation (Jepps et al, 2011; Iannotti et 
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al., 2013). Given its wide expression in the inner ear, it is not surprising that 
mutations in Kv7.4 are associated to an hereditary, non-syndromic, progressive 
form of sensorineural hearing loss called DFNA2 (Kubisch et al., 1999). Most 
DFNA2-causing mutations in Kv7.4 are missense alterations affecting amino 
acids located within or close to the channel pore or C–terminal region and 
causing hearing loss via a dominant-negative effect, often with a severe 
phenotype; deletions, which cause DFNA2 via haploinsufficiency, and are 
assocated to a later-onset of symptoms compared to missense mutations (Smith 
and Hildebrand, 2008). 
Kv7.5. Last Kv7 channel to be cloned, kcnq5 gene products are expressed in 
nervous system and they largely overlap Kv7.2 and Kv7.3 distribution, thus 
suggesting that it does contribute to the molecular heterogeneity of M-current. 
In particular, Kv7.5 do assemble with Kv7.3 and Kv7.4 but not with Kv7.2; it has 
been proposed that Kv7.5 expression in heteromeric channels is a way to reduce 
M-current, possibly by “sequestering” Kv7.3 subunits available to form the more 
“efficient” Kv7.2/Kv7.3 heteromers, known to underlie larger currents. As for 
other Kv7 channels, Kv7.5 expression has been individuated also in non-
neuronal tissues, such as smooth and skeletal muscle (Jepps et al., 2011; 
Iannotti et al., 2010).  
 
BFNS 
Mutations in Kv7.2 and Kv7.3 are associated to Benign Familial Neonatal 
Convulsions (BFNS), a neonatal form of epilepsy characterized by an early age of 
onset (day 3) and by the spontaneous disappearing of symptoms between the 
first and the sixth to 12th month of life.  BFNS phenotype is characterized by a 
wide spectrum of seizure types (tonic or apneic episodes, focal clonic activity, or 
autonomic changes), usually lasting one or two minutes; symptoms may be 
confined to one body part, migrate to other body regions, or generalize. Most 
patients develop normally, although about 10%-15% of individuals with BFNS 
may experience epileptic seizures later in life (Bellini et al., 2010). 
Haploinsufficiency seems to be a main pathogenetic mechanism, since reduction 
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of M-current density by only 25% is sufficient for the onset of BFNS. Several 
hypotheses have been made to explain the disappearance of seizures with brain 
development; among them, some concern IKM and Kv7.2 subunits expression, 
while others focus on differences in inhibitory conductance in neonatal brain 
when compared to adult one. In particular, it has been suggested that fetal 
neurons express a shorter and non-functioning  Kv7.2 splice variant (Smith et 
al., 2001), or that Kv7.2 subunits show a different subcellular distribution in 
adult neurons with respect to immature ones (Weber et al., 2006); moreover, it 
has been demonstrated that M-current density increases after the birth, thus 
contributes to disappearance of recurrent synchronous bursts characteristic of 
early phases of hippocampal development (Safiulina et al, 2008). On the other 
hand, it is known that in immature brain, due to prevalent activity of the co-
transporter Na+-K+-2Cl- (NKCC1), chloride gradient is inverted; therefore, 
activation of GABA receptors mediate cell-depolarization thus giving an 
excitatory stimulus rather than inhibit  neurotransmission (Okada et al, 2003). 
As a consequence, neonatal brain might be more sensible to M-current 
dysfunction, thus leading to epilepsy that disappears in adulthood.  
Despite the common “benign” phenotype associated to mutations in Kv7.2 and 
Kv7.3, several recent studies have described kcnq2 gene alterations in neonates 
affected by more severe neurological disorders known as Kv7.2 related neonatal 
epileptic encephalopathy (kcnq2-NEE), such as pharmacoresistant seizures with 
psychomotor retardation (Nabbout and Dulac, 2011), neuroradiological 
alterations (mostly affecting basal ganglia and thalamus), as well as Ohtahara 
syndrome, an early-onset age-related epileptic encephalopathy characterized by 
typical suppression-burst EEG pattern within the first months of life and poor 
outcome in terms of psychomotor development and seizure control (Bellini  et 
al., 2010). The reasons of such a wide spectrum of phenotypes caused by 
mutation in the same gene are not completely understood; differences in the 
type of mutations as well as protein-region affected, and their functional 
consequences on channel expression and/or activity is a possible explanation.   
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Animal models for Kv7 channels-associated diseases 
Pahophysiological role of M-current has been evaluated in different animal 
models that reproduced the loss of Kv7 subunits by deleting gene expression 
(knock-out mouse) or by the introduction in the genome of modified channels 
with dominant-negative effects (transgenic mice). Among them we can mention: 
 Kv7.2- Kv7.3. Two animal models for BFNS have been obtained by the 
introduction in Kv7.2 and Kv7.3 genes of two human BFNS-causing 
mutations in two different mice-strains, to better understand also the 
possible interference of genetic background (Singh et al, 2008). The 
mutations (A306T in Kv7.2 e A311V in Kv7.3) affected pore-region, thus 
causing a dramatic decrease of channel activity. Homozygous mice for 
Kv7.2-A306T or Kv7.3- A311V showed early onset spontaneous 
generalized tonic-clonic seizures, with electro-encephalographic 
alteration suggesting a lymbic origin of convulsions. Moreover, adult 
homozygous mice had recurrent seizures that triggered molecular 
plasticity including ectopic neuropeptide Y (NPY) expression; in addition, 
overall mortality was increased when compared to control littermate, 
with differences depending on mutation and murine strain. Interestingly, 
despite the severe phenotype, no significant morphological alteration, 
such as hippocampal mossy fibers sprouting or neuronal loss, was found 
in homozygous mice, thus paralleling the normal neurodevelopmental 
cognitive profile exhibited by most BFNS patients (Singh et al., 2008). 
 Kv7.4. Two animal models of Kv7.4 function knock-down are available: a 
knock-out (Kv7.4-/-) and a transgenic mouse in which a DFNA2-causing 
mutation exerting dominant negative effects on wild-type Kv7.4 has been 
introduced (Kv7.4dn/dn) (Kharkovets et al, 2006). Both mice display an 
apparent normal phenotype in early phases, while hearing function is 
progressively impaired later in life, due to death of cochlear outer hair 
cells, where Kv7.4 expression seems to be particularly abundant; this 
phenotype reproduce the progressive sensorineural hearing loss showed 
by DFNA2 patients. It has been suggested that cell death is a consequence 
of chronic depolarization determined by lack of Kv7.4-mediated currents. 
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 Kv7.5. A transgenic mouse carrying a mutation in Kv7.5 (similar to the 
one in Kv7.4 used to generate Kv7.4dn/dn mouse model) exerting dominant 
negative effects has been recently generated (Tzingounis et al, 2010).  
Such mouse showed no apparent clinically-relevant phenotype and 
normal brain morphology; however, in the CA3 area of hippocampus, a 
region that highly expresses Kv7.5 channels, a decrease in the medium 
and slow afterhyperpolarization currents was observed. 
 
Drugs acting on Kv7 channels 
Given the rising interest in M-channels pathophysiology and related possible 
therapeutic opportunities, a number of compounds acting on Kv7 subunits have 
been developed throughout years. Moreover, although some of them are not in 
clinical use, Kv7 activators and blockers do represent a valid tool to further 
understand M-current role. 
Blockers. Linopiridine is one of the first molecules identified as Kv7-blockers. 
Since it increases release of different neurotransmitters, such as acetylcholine, 
serotonin, dopamine and glutamate in different animal models, linopiridine has 
been proposed as a cognition enhancer. Nonetheless, clinical trials investigating 
its efficacy in diseases characterized by cognitive impairment such as 
Alzheimer’s Disease failed to demonstrate symptoms improvement, possibly 
because of its low potency on Kv7 channels as well as a negative 
pharmacokinetic profile with consequent cholinergic side effects. Linopiridine 
analogues such as XE-991 have been developed with the aim to overcome such 
issues; however, their use is still restricted to pre-clinical phases (Wulff et al., 
2009).   
Activators. Flupirtine is a triaminopyridine successfully used in clinical practice 
in some European countries since 1984 for its centrally acting, nonopioid 
analgesic properties, but without notable anti-inflammatory and antipyretic 
activity. It is also provided with muscle relaxant actions, thus suggesting its use 
in muscular pathology such as fibromyalgia. Later, flupirtine was shown to have 
also antioxidant, neuroprotective and anticonvulsant activity, although at doses 
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higher than those producing analgesia. Structure-activity optimization of 
flupirtine yielded retigabine (chemical name N-(2-amino-4-(4-
fluorobenzylamino)-phenyl)-carbamic acid ethyl ester), the prototype IKM 
opener. Retigabine displayed more effective anticonvulsant activity when 
compared to flupirtine, being active in nearly every animal seizure model, with 
an overall profile different from any other known drug (Porter et al., 2007). In 
addition to the activation of Kv7-mediated current,  retigabine also potentiates 
GABAA-mediated currents at concentrations at least 10–30 times higher than 
those effective on M-current; a weak blocking action on ligand- (kainate and 
NMDA receptors) and voltage-gated (sodium and calcium) channels were also 
observed (Rundfeldt, 1997 and 1999). As flupirtine, retigabine exerts 
antioxidant activity in vitro (Boscia et al., 2006; Gassen et al., 1998), a 
pharmacological property which might explain at least in part the 
neuroprotective effects shown by this compounds. Retigabine increases IKM by 
determining an hyperpolarizing shift in the voltage-dependence of the channel 
activation process and an increase in the maximal opening probability of these 
channels; although the size of these effects is different depending on channel 
subunits composition (higher in Kv7.2 and Kv7.3 homo- and hetero-mers, lower 
for Kv7.4 and Kv7.5), retigabine is considered a non-selective Kv7 activator. 
Noticeably, retigabine does not activate cardiac Kv7.1 channels. By contrast, a 
higher subunit-selectivity is a characteristic of ICA-27243, a compound 
belonging to the chemical class of substituted benzamides. ICA-27243 has also 
anticonvulsant properties, as demonstrated by studies in preclinical models of 
seizures (Wickenden et al., 2008), and preferentially activates current elicited 
by Kv7.2/Kv7.3 heterotetramers, while its potency on Kv7.4 or Kv7.3/Kv7.5 
channels is 20-fold and-100-fold lower, respectively (Roeloff et al., 2000). Other 
molecules provided with agonistic activity on Kv7 channels are zinc pyrithione 
(Xiong et al., 2007), which potentiates K+ currents elicited both by cardiac Kv7.1 
and neural Kv7.2-5 subunits, except those sustained by Kv7.3 channels,  BMS-
204352, originally developed as an opener of BKCa channels (Korsgaard et al., 
2005), and the acrylamide compound, (S)-1 (Bentzen et al, 2006), both 
displaying a stronger action on channels formed by Kv7.4 subunits, and 
NS15370, a more potent retigabine-analogue able to activate all Kv7 subunits at 
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sub-micromolar concentrations (Dalby-Brown et al., 2013). Interestingly, 
commonly used drug as diclofenac can also activate M-current. In particular, it 
has been demonstrated that diclofenac-derivatives with poor or absent 
cyclooxygenase-blocking activity reduced neuronal excitability and/or showed 
anticonvulsant effects in murine models of seizures (Peretz et al., 2007 a and b). 
A better understanding of the differential subunit selectivity of Kv7 activators 
has been achieved by studies on drug-binding sites. For instance it has been 
suggested that retigabine binds to a hydrophobic pocket located between the 
cytoplasmic parts of the S5 and the S6 transmembrane domains in the open 
channel configuration, where a tryptophan residue in the intracellular end of 
the S5 helix (W236 in the Kv7.2 sequence) seems to play a crucial role (Wuttke 
et al., 2005; Schenzer et al., 2005). Indeed, replacement of this residue with a 
smaller and less hydrophobic amino acid (leucine) largely impeded the ability of 
retigabine to increase M-current. Additional aminoacids (in Kv7.2 sequence: 
Leu243 in S5, Leu275 within the inner pore loop, Gly301 in the S6 segment, and 
Leu299 in S6 of the neighboring subunit) seem also to be involved in the 
formation of the complete retigabine binding site (Lange et al., 2009); 
interestingly, except for Leu275, these amino acids are conserved among all 
neural Kv7 subunits but are missing in the Kv7.1 subunit primary sequence, thus 
possibly explaining the lack of effect of retigabine on Kv7.1 subunits. The 
tryptophan in the S5 segment seems also to be important for the binding of 
other IKM activators, such as S-(1) and BMS-204352, while zinc pyrithione, are 
supposed to bind to a different aminoacid sequence in the pore. These 
observations might explain the additive effects on IKM exerted by retigabine and 
zinc pyrithione (Xiong et al., 2008). By contrast, diclofenac and its derivatives 
binding site seems to be in close proximity to the external surface of the voltage-
sensing domain, at the interface of helices S1, S2, and S4. Indeed, these 
compounds are still able to potentiate the K+ currents elicited by the Kv7.2 
W236L mutant. Similar to these drugs, the selective Kv7.2/Kv7.3 opener ICA-
27243 was also found to bind to the voltage-sensing domain; the primary 
sequence of the region involved in ICA-27243 binding appears extremely 
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variable among Kv7 subfamily members, allowing the drug to selectively affect 
channels formed by specific Kv7 subunits. 
 
Figure 5. (A) Schematic topology of a single Kv7.2 subunit, with amino acids involved in 
retigabine binding are indicated. (B) top view of the overall structure of the channel formed by 
four identical Kv7.2 subunits, with one retigabine molecule bound. (C) enlarged view of the 
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retigabine binding site with the retigabine molecule docked into the channel cavity. From 
Barrese et al., Clin Pharmacol. 2010. 2:225-36) 
 
KV7 channels and neurodegeneration 
The role of Kv7 channels in the regulation of cell death/survival, or protection 
from damage in neurons, in particular in the hippocampus, has been 
investigated in various experimental studies. Such studies do not clearly 
establish a neuroprotective or neurodegenerative role for Kv7 channels, 
probably because of the different experimental models used. 
Indeed, it has been recently demonstrated that the activation of Kv7.2/Kv7.3 
channels induced by the non-specific oxidant NEM could induce death in 
hippocampal primary neuronal culture, through the activation of the apoptotic 
pathway; this effect was reverted by the Kv7-selective blocker XE-991 or by 
exposure to high extracellular potassium concentration (Zhou et al., 2011).  
On the other hand, other studies have pointed out the neuroprotective effects of 
IKM-activators in different experimental models, such as hippocampal 
organotypic slice cultures (OHSCs) treated with NMDA or undergoing serum 
deprivation (Boscia et al., 2006), although in these models the neuroprotective 
effects of retigabine seem to be due to a non-specific anti-oxidant action more 
than a direct activation of M-current. According to this study, neuroprotective 
effects of flupirtine and retigabine are more noticeable in some hippocampal 
areas such as dentate gyrus, a brain region showing remodelling after chronic 
epileptogenic stimuli. Similarly, Gamper and collaborators (2006) demonstrated 
that exposure to retigabine reduced oxygen glucose deprivation (OGD)-induced 
death of OHSCs. 
 Flupirtine- and retigabine-induced neuroprotection has also been observed in 
two “in vivo” preclinical models of ischemia, namely the four vessels occlusion 
(4-VO) rat (Block et al, 1997) and a mouse model of cerebral photo-induced 
thrombosis (Bierbower et al, 2011); in both animal models, these drugs reduced 
infarct area and/or the subsequent cognitive impairment.  
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RATIONALE AND AIM OF THE STUDY 
Many neuronal diseases are characterized by hyper-excitability. For 
instance, ischaemic stroke causes the activation of multiple processes, including 
ionic imbalance, increase in the extracellular concentration of glutamate and 
activation of the NMDA receptors, with following increase in intracellular 
calcium and cell death, peri-infarct depolarization (Doyle et al., 2008); epilepsy 
shows similar pathogenetic mechanisms (Costa et al., 2006). Excessive 
neurotransmitter release is a key events in the propagation of neuronal damage, 
and subsequent death, following ischaemia. Although glutamate release (and in 
particular on NMDA receptor over-stimulation) has been viewed as a main 
cause of neuronal damage, massive release of monoamine neurotransmitter 
such as dopamine, also occurs immediately following the onset of ischemia 
(Sarna et al., 1990). In particular DA levels achieved immediately following the 
onset of ischemia have been shown to be neurotoxic and directly contribute to 
the resulting cell death (Lieb et al., 1995).  Given their demonstrated role in 
regulating neurotransmitter release in different brain areas (Martire et al., 
2004), Kv7 channels might be interesting target in counteracting the abnormal 
modification occurring in hyper-excitability pathology such as stroke.  
The prominent role of Kv7 channels (in particular Kv7.2) in reducing neuronal 
excitability is underlined by inherited disease due to mutations in Kv7.2 and 
Kv7.3, Benign Familial Neonatal Seizures. Interestingly, several recent reports 
have described alterations in Kv7.2 gene also in patients with pharmacoresistant 
epilepsies with psychomotor retardation, as well as in cases of epileptic 
encephalopathy (Weckhuysen et al., 2011). The molecular basis of such 
variability is still unknown, although it has been proposed that specific 
alterations affecting distinct aminoacids or different regions of the channel 
could explain the onset of “benign” epileptic phenotype rather than a severe 
encephalopathy. 
Based on these premises, the aim of this study has been to investigate: 
 The potential neuroprotective role of Kv7 channels in an in vitro model of 
ischemia, such as brain slices undergoing oxygen- and glucose- 
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deprivation. In particular, we have investigated the effects of the 
pharmacological modulation of Kv7 channels on dopamine release and 
on brain damage in slices obtained from rat caudate, a region primarily 
involved in ischemic stroke.  
 The possible molecular basis of the different phenotypes caused by 
mutation in Kv7.2. In particular we have investigated the effects on the 
channel function determined by two mutations affecting the same 
residue in the voltage sensing domain of Kv7.2, namely R6Q and R6W, 
responsible for a form of epileptic encephalopathy and BFNS, 
respectively.  
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MATERIALS AND METHODS 
Animal and slices. Adult male Wistar rats mice (10–12 weeks old) were killed 
by cervical dislocation, and the vault of the skull was rapidly opened to expose 
the brain, while being frequently irrigated with ice cold maintenance artificial 
cerebrospinal fluid (aCSF, composition in mM): NaCl (126.0), KCl (2.0), KH2PO4 
(1.4), MgSO4 (2.0), NaHCO3 (26.0), CaCl2 (2.4), (+)-glucose (10.0), bubbled for at 
least 30 min with 95% O2/5% CO2.  The brain was then removed and placed in 
ice cold maintenance aCSF until slicing (less than 5 min). The brain was 
dissected quickly and coronal slices (400 m thick) at the level of the striatum 
were cut and maintened in aCSF continually bubbled with 95% O2/5% CO2. 
Once cut, slices were left to equilibrate for 1–4 h at room temperature (21±1 
◦C), to allow recovery from any trauma associated with slicing (Toner and 
Stamford, 1996).  
Fast Cyclic Voltammetry (FCV). The FCV recording apparatus comprised a slice 
chamber (approx. 2 ml) which was suspended over a water chamber and heated 
via a thermostatically controlled circulating water bath (Grant, Cambridgeshire, 
UK) and continuously perfused with normal- or OGD- aCSF (2 mM glucose, 
bubbled with 95% N2/5% CO2), kept at a temperature of 32.ºC, with a flow rate 
of 100 mL/h. FCV microelectrode was placed into the dorsolateral caudate 
nucleus, at a depth of approximately 75 m below the slice surface, using a 
micromanipulator under microscope guidance. DA levels in the dorsolateral 
caudate nucleus were measured continuously by FCV at carbon fibre 
microelectrodes (Stamford, 1990). The signal was also digitalized and recorded 
using Spike7 software (Molecular Devices, CA). An increase in the current signal 
at +600 mV, together with a corresponding reduction peak at −200 mV, were 
characteristic of DA detection in the caudate nucleus (Stamford, 1990). 
Experimental protocol for oxygen- and glucose- deprivation. Slices were 
allowed to equilibrate in FCV slice chamber for 15 min, to assess that no 
spontaneous dopamine release occured. They were then incubate with normal 
aCSF containing DMSO (control) or drug (treated) for 15min; insults were 
determined by superfusion of brain slices with OGD-aCSF, containing DMSO 
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(control) or drug (treated). For qPCR, western blot and TTC staining 
experiments, slices were also exposed for 30 min to normal aCSF containing 
DMSO or drug after OGD-superfusion, to mimic reoxygenation. 
 FCV data analysis. Analysis of data was performed offline using Spike7. 
Perfusion with OGD-aCSF typically evoked a large increase in DA from the slice 
and four parameters were measured: (1) time to onset of DA release from the 
initiation of OGD superfusion (T[on]); (2) time taken to reach maximum DA 
release after the onset of release (T[peak]); (3) maximum extracellular DA 
concentration (DA[max]); and (4) mean rate of DA release (DA/T). 
 
Figure 6. Variables recorded from voltammetry experiments. This figure is a close up from the 
dopamine release event brought on by OGD. See text for more information (from Davidson et al., 
2011).  
TTC staining. Slices were stained with 2,3,5-triphenyltetrazolium chloride 
(TTC) used at a dilution of 0.125% (w/v) in aCSF at room temperature in the 
dark for 30 min, then fixed in 4% paraformaldehyde solution; slices were 
photographed and analysed for percentage of caudate nucleus area stained, 
using ImageJ software (http://rsb.info.nih.gov/ij/). 
Real time PCR. Total RNA was extracted from brain slices using the RNeasy 
Mini kit (Qiagen, U.K.) RNA was quantified using a Nanodrop 
Spectrophotometer (LabTech International) and reverse transcribed with Oligo 
(dT) primers and Moloney Murine Leukemia Virus (M-MLV; Invitrogen, U.K.). 
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Negative controls (RT-) were carried out in the absence of reverse transcriptase 
to check for genomic contamination. Quantitative mRNA analysis was 
determined using Precision-iC SYBR green master mix (PrimerDesign, Ltd., U.K.) 
with the CFX96 (Biorad, U.K.). Duplicate reactions were performed in 20μl 
volumes including 300nM primer mix (forward and reverse primer; 
PrimerDesign, Ltd., U.K.). Amplification protocol was as follow: 95°C for 10 min, 
40 cycles of 95°C for 15 s, and 60°C for 1 min, during which time data was 
collected. Melt curve analysis, to ensure each primer set amplified a single 
product, completed the protocol and no template controls (NTCs) were run 
alongside all reactions to assess contamination. Cycle threshold (Ct) values were 
determined using Bio-Rad CFX96 software and the single threshold mode. 
Relative abundance of each gene of interest was calculated and normalised to 
the mean of gapdh housekeeping gene, using the 2-Ct formula.  
Western Blot. Brain slices were homogenized in 100 μL of lysis buffer (in 
mmol/L: 20 Tris base, 137 NaCl, 2 EDTA, 1% NP40, 10% glycerol, pH 8, and 10 
μL/mL protease inhibitor cocktail; Sigma-Aldrich), incubated on ice for 30 
minutes, centrifuged to remove cell debris, and denatured at 95°C for 5 minutes 
in the presence of sample buffer and reducing agent (Invitrogen). Samples were 
then loaded onto SDS-PAGE gels (4–12% Bis-Tris, Invitrogen), subjected to 
electrophoresis, and then transferred onto a polyvinylidene fluoride membrane 
(Amersham Biosciences). The membrane was then probed with an anti- Kv7.2 
antibody (1:500; Millipore). Protein bands were visualized with enhanced 
chemiluminescence (Thermo Scientific) and hyperfilm (Amersham Bioscience). 
The membrane was then washed in PBS-Tween (0.1%) and subsequently 
reprobed for β-actin (1:5000; Sigma-Aldrich, A1978), used as loading control. 
Bands were quantified with Image J software.  
Mutagenesis of Kv7.2 cDNA and Heterologous Expression of WT and Mutant 
KV7.2 cDNAs. Mutations were engineered in human Kv7.2 cDNA cloned into 
pcDNA3.1 by sequence overlap extension PCR with the Pfu DNA polymerase as 
described previously (Miceli et al., 2009). Briefly, mutations were introduced by 
amplifying, in three PCR reactions, a PmlI and HindIII cassette, subsequently 
cloned in pcDNA3.1 plasmid. Channel subunits were expressed in CHO cells by 
29 
 
transient transfection using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. A plasmid encoding for EGFP (Clontech) was used as 
transfection marker.  
 
Whole-Cell Electrophysiology. Currents from CHO cells were recorded at room 
temperature (20–22 °C) 1 to 2 d after transfection by using an Axopatch 200A 
(Molecular Devices) and the whole-cell configuration of the patchclamp 
technique, with glass micropipettes of 3 to 5 MΩ resistance. The extracellular 
solution contained (in mM) 138 NaCl, 2 CaCl2, 5.4 KCl, 1 MgCl2, 10 glucose, and 
10 Hepes, pH 7.4 adjusted with NaOH; the pipette (intracellular) solution 
contained (in mM) 140 KCl, 2 MgCl2, 10 EGTA, 10 Hepes, 5 Mg-ATP, pH 7.3 to 
7.4 adjusted with KOH. pCLAMP software (version 10.0.2) was used for data 
acquisition and analysis. Currents were corrected offline for linear capacitance 
and leakage currents by using standard subtraction routines (Clampfit module 
of pClamp 10). To generate conductance–voltage curves, the cells were held at 
−80 mV, then depolarized for 1.5 s from −80 mV to +20/+120 mV in 10-mV 
increments, followed by an isopotential pulse at 0 mV of 300 ms duration. 
Current values at the beginning of the 0-mV pulse were measured, normalized, 
expressed as a function of the preceding voltages, and fitted to a Boltzmann 
distribution of the form y = max/[1 + exp(V1/2 − V)/k] to obtain V1/2 and slope 
factor k. Current traces were fit to a single- or a double-exponential function. 
 
Computational Modeling. All simulations were carried out with the NEURON 
program, version 7, by using a previously described 3D model of a CA1 
pyramidal neuron. Uniform passive properties were used over the entire 
neuron, with Cm of 0.75 μF/cm2 and Rm of 37.3 kΩ/cm2 (τm = 28 ms). Active 
somatic and dendritic properties included the following conductances: sodium 
(INa), potassium delayed rectifier (IDR), potassium transient (IA), potassium M 
(IKM), and nonselective, hyperpolarization-activated (Ih); a low-threshold Ca2+ 
and a Ca2+-dependent K+ conductance, as well as a simple Ca2+ extrusion 
mechanism, were also included. INa, IDR, Ca2+-, and Ca2+-dependent K+ 
conductances were included at uniform density over the somatodendritic 
region, and IA and Ih linearly increasing with distance from the soma. The IKM 
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properties were implemented to fit the steady-state and kinetic values obtained 
in this work.  
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RESULTS 
In previous studies conducted by our research group, it was demonstrated that 
pharmacological modulation of M-current modified neurotransmitters release 
in different brain areas (Martire et al., 2004). In particular, Kv7 activator 
retigabine was able to decrease dopamine release in striatal synaptosomes 
exposed to high extracellular K+ concentrations. Effects of retigabine were 
concentration-dependent, with an IC50 of about 0.5 M (Martire et al., 2007).  
 
Figure 7. Effects of retigabine on high extracellular K+-evoked dopamine release on rat striatal 
synaptosomes. From Martire et al., 2007 
  
Since striatum is a brain area often damaged in most cases of ischemic stroke, 
and given that massive dopamine release occurs during ischemia, reaching 
neurotoxic levels and contributing to the propagatation of brain damage (Lieb et 
al., 2010), we investigated the potential role of Kv7 channels in modulating brain 
damage induced by anoxia in the striatum, using brain slices undergoing 
oxygen- and glucose- deprivation (OGD) as an experimental model of ischemia. 
This in vitro model confers some advantages such as the possibility to control 
the chemical environment and the temperature, factors which both affect 
neurological outcome following OGD or the avoidance of the use of anaesthetics, 
which are known to affect neurotransmitter function and can be 
neuroprotective. Dopamine release was measured by means of Fast scan Cyclic 
Voltammetry (FCV), an electrochemical technique that can be used to monitor 
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release of endogenous monoamines levels because of their property to be 
oxidized at low voltages. In particular, a triangular-shape voltage that is 
sufficient to oxidize dopamine is applied to a carbon fiber microelectrode; 
dopamine is oxidized to form dopamine-o-quinone which is reduced back to 
dopamine. During this redox reaction electrons are transferred between 
molecules and the microelectrode (electrolysis), thus producing a current flow 
at the electrode surface that is directly proportional to dopamine molecules 
present in the fluid. If current are plotted against the applied potential, it is 
possible to obtain a cyclic voltammogram, which is unique for each substance 
and allows to recognize the molecular identity of the molecule (John and Jones, 
2007).  
 
Figure 8. Voltammetric detection of OGD-evoked dopamine. (A) input voltage waveform to the 
carbon fibre electrode. The applied voltage consists of a triangular waveform, going from 0 to -1 
then up to +1.4, back to -1 and then back to 0 V. (B) current evoked by the input voltage at the 
carbon fibre electrode. The solid line is the current prior to OGD-evoked dopamine efflux and 
the dotted line shows the current at peak dopamine efflux following OGD (From Davidson et al., 
2011). 
 
This technique offers some advantages, such as the possibility to measure 
endogenous dopamine (thus avoiding possible artefacts due to labelled-
neurotransmitters overload that are commonly used in neurochemistry 
experiments) or the opportunity to evaluate “real-time” release with sub-second 
time resolution. 
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Effects of Kv7 modulators on anoxia-induced dopamine release 
To investigate whether pharmacological modulation of Kv7 channels activity 
might interfere with the pathological consequences prompted by anoxia 
(possibly obtaining further information on the specific Kv7 subunit involved), 
we tested the effects of several drugs acting on Kv7 channels, provided with 
different subunit-specificity and pharmacological profile on OGD-induced 
dopamine release. Exposure of striatal slices to oxygen- and glucose- deprived 
artificial cerebrospinal fluid (OGD) causes a release of endogenous dopamine 
after about 8-10 minutes (time to onset, T-on), fastly reaching a peak (dopamine 
maximun concentration). Neural Kv7 activator retigabine, at the concentration 
of 1M, delayed by about 30% such increase (130.62±7.35% with respect to 
control, thus determining an increase in time to onset), and also reduced 
dopamine peak (DApeak) and rate of change of dopamine efflux (DA/Tpeak), by 
about 40 and 60% respectively, when compared to vehicle-treated slices (DApeak 
56.54±12.01; DA/Tpeak 39.83±8.93) (Fig.9).  
 
Figure 9. Effect of RT 1M on voltammetric parameters. Data are expressed as % of DMSO-
treated slices (control). Data are expressed as mean±S.E.M. (n=7 for both DMSO- and RT- treated 
slices). *=p<0.05   
 Another Kv7.2/Kv7.3-preferring activator, ICA27243, at the concentration of 
1M reduced dopamine peak by 60% (42.83±10.14% of control) while it did not 
significantly affect time to onset (101.60±18.90%). ICA27243 also reduced time 
to reaching dopamine peak by about 60%, although the speed to achieve 
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maximum dopamine concentration (rate of change of dopamine) was not 
significantly different when compared to control slices (Tpeak 43.77±10.05%; 
DA/Tpeak 120.72±34.74% with respect to controls) (Fig 10). 
 
Figure 10. Effect of ICA27243 1M on voltammetric parameters. Data are expressed as % of 
DMSO-treated slices (control). Data are expressed as mean±S.E.M. (n=6 for both DMSO- and ICA- 
treated slices). *=p<0.05   
By contrast Kv7 activator NS15370 (a more potent Kv7 opener with respect to 
retigabine) at the concentration of 0.1M almost doubled time to reach 
dopamine peak with respect to vehicle-treated slices (199.82±34.14%), but it 
showed no significant effects on other parameters (T-onset: 99.48±21.10; 
DA/Tpeak: 91.21±35.92% vs controls) (Fig 11). 
35 
 
 
Figure 11. Effect of NS15370 0.1M on voltammetric parameters. Data are expressed as % of 
DMSO-treated slices (control). Data are expressed as mean±S.E.M. (n=4 for both DMSO- and NS- 
treated slices). *=p<0.05   
 
Then we tested two different pan-Kv7 blockers, in particular XE991, and 
linopiridine. While XE991, although causing a variable and not-significant 
increase the rate of change of dopamine (187.60±67.66%), did not interfere 
with dopamine release from caudate (103.65±8.92) (Fig 12), linopiridine 10 M 
showed a 4-fold increase in dopamine peak and rate of dopamine, thus 
suggesting a possible neurotoxic effect of Kv7 channels blockade (DApeak 
417.19±84.89%; DA/Tpeak 435.60±75.13% with respect to controls) (Fig 13). 
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Figure 12. Effect of XE991 10M on voltammetric parameters. Data are expressed as % of 
DMSO-treated slices (control). Data are expressed as mean±S.E.M. (n=7 for both DMSO- and 
XE991- treated slices). *=p<0.05   
 
Figure 13. Effect of linopiridine 10M on voltammetric parameters. Data are expressed as % of 
DMSO-treated slices (control). Data are expressed as mean±S.E.M. (n=7 for both DMSO- and 
LINO- treated slices). *=p<0.05   
 
In addition, when incubated together with retigabine, Linopiridine 10M was 
able to prevent the changes in time to onset, dopamine maximum concentration 
and rate of change of dopamine release induced by retigabine after OGD 
superfusion (Fig14).    
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Figure 14. Effect of linopiridine 10M co-incubated with retigabine1M on voltammetric 
parameters. Data are expressed as % of DMSO-treated slices (control). Data are expressed as 
mean±S.E.M. (n=5 for both DMSO- and LINO- treated slices). *=p<0.05   
  
Effects of Kv7 modulators on anoxia-induced damage 
To further investigate whether the reduced dopamine release caused by Kv7 
activators could determine also a decrease in on brain slices damage induced by 
OGD, we performed TTC staining experiments, a widely-used and fast method to 
measure cell viability in histological sections. In these experiments, brain slices 
were incubated in normal aCSF for 30 minutes after the OGD insult, to allow 
brain damage to be evaluated. Exposure of brain slices to OGD medium caused a 
loss in TTC staining compared to control slices by about 40% (61.80±4.68% 
with respect to control). Retigabine (at concentrations ranging from 0.3 to 
10M) was able to reduce the loss of TTC staining induced by OGD, in a dose-
dependent manner, with the higher effect shown at concentrations of 10M 
(84.27±9.17% versus control) (Fig15). 
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Figure 15. (A) Representative images showing TTC staining on brain slices incubated in normal 
aCSF (ctl), OGD+vehicle or OGD+RT 1M. (B) Quantification of the effects on TTC staining 
exerted by increasing concentrations of retigabine in OGD-exposed slices. Data are expressed as 
% of normal aCSF-incubated slices (control). Data are expressed as mean±S.E.M. (n= at least 5 
for each experimental point). *=p<0.05   
Moreover, ICA27243 (at concentration ranging from 0.1 to 10M) dose-
dependently prevented the loss of TTC staining in brain slices exposed to OGD 
(vehicle-treated slice: 69.64±2.06%; ICA27243 10M-treated: 89.06±8.64% 
with respect to control) (Fig 16).   
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Figure 16. (A) Representative images showing TTC staining on brain slices incubated in normal 
aCSF (ctl), OGD+vehicle or OGD+ICA27243 1M. (B) Quantification of the effects on TTC staining 
exerted by increasing concentrations of ICA27243 in OGD-exposed slices. Data are expressed as 
% of normal aCSF-incubated slices (control). Data are expressed as mean±S.E.M. (n= at least 5 
for each experimental point). *=p<0.05   
 
By contrast, exposure of brain slices to different concentrations of linopiridine 
did not have any effect at lower doses, but it enhanced OGD-induced loss of TTC 
staining only at the higher concentration tested (30M; 60.26±6.16% compared 
to 80.23±3.65% of vehicle-treated slice) (Fig17). 
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Figure 17. Quantification of the effects on TTC staining exerted by increasing concentrations of 
Linopiridine in OGD-exposed slices. Data are expressed as % of normal aCSF-incubated slices 
(control). Data are expressed as mean±S.E.M. (n= at least 5 for each experimental point). 
*=p<0.05   
  
Moreover, co-incubation of Linopiridine 10M reversed the reduction in loss of 
TTC-staining exerted by retigabine at the concentration of 1M (Fig18).  
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Figure 18. Quantification of the effects on TTC staining exerted by RT 1M and RT 
1M+Linopiridine 10M in OGD-exposed slices. Data are expressed as % of normal aCSF-
incubated slices (control). Data are expressed as mean±S.E.M. (n= at least 5 for each 
experimental point). *=p<0.05    
 
Effects of anoxia-reoxygenation on Kv7 channels expression 
Since activation of M-current seems to reduce damage induced by anoxia and 
glucose deprivation, possibly with slight differences depending on the 
compound used and its subunit-selectivity, we next evaluated the possible 
changes in Kv7 subunits expression levels after OGD insults. Exposure of striatal 
brain slices to (OGD) for 15 minutes and subsequet incubation in normal 
artificial cerebrospinal (aCSF) fluid for 30 minutes caused a   6-fold decrease in 
the trascript of Kv7.2 gene measured by real-time PCR; levels of mRNAs 
encoding for other Kv7 subunits seemed to be unaffected by anoxia-reperfusion 
insult (Fig 19A). Western blot experiments showed a parallel, although less 
evident, reduction in Kv7.2 protein levels in brain slices exposed to OGD (by 
about 50%) (Fig 19B).  
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Figure 19. (A) Quantification of mRNA levels encoding for Kv7 subunits in striatal slices 
exposed to normal aCSF (control) or OGD. Data are normalized to housekeeping gene (gapdh) 
and expressed as relative to the average of controls, using the 2-Ct formula. Data are expressed 
as mean±S.E.M. (n= 5 for both control abd OGD slices). *=p<0.05. (B) Western blot analysis for 
Kv7.2 protein expression on total lysates from control- or OGD-treated slices. The inset shows a 
representative blot for Kv7.2 and -actin. The approximate molecular mass for each of these 
proteins (expressed in kDa) is shown on the left. Bar graph shows the quantification of the 
averaged OD values for the Kv7.2 bands, normalized to the OD value for -actin, in both control- 
(solid columns) and OGD-exposed (open columns) slices. *p ≤ 0.05 vs. respective control; n=5 
for both control- and OGD-exposed slices.  
 
KV7.2 and encephalopathy 
The results shown before suggest that changes in the activity of Kv7 channels 
might represent a relevant event in the pathological cascade leading to brain 
dysfunction and damage. This potential role of Kv7 channels, in particular Kv7.2, 
is underlined by the finding that mutations in Kv7.2 gene can lead not only to 
BFNS, but also to severe form of neuronal diseases, such as pharmacoresistant 
epilepsy or encephalopathy. Such heterogeneous phenotypes might be due to 
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distinct mutations, differently affecting channel function. To better understand 
this phenomenon, we investigated the functional changes prompted by two 
mutations in the fifth arginine residue of the S4 transmembrane domain 
belonging to the voltage sensing domain of Kv7.2 channel (R213 or R6). This 
residue, together with other positively-charged aminoacid in the S4 segment, is 
highly conserved among different potassium channels and play a fundamental 
role in sensing changes of membrane potential, thus causing the channel gating 
(Fig20).  
 
Figure 20. Topological representation of a Kv7.2 subunit (top) and equence alignment of the S4 
segments of the indicated Kv subunits (bottom), with the R213 (R6) residue highlighted. 
Residues are colored according to the following scheme: magenta, basic; blue, acid; red, 
nonpolar; and green, polar. 
 
Patch clamp recordings in CHO cells transfected with wild type or mutant Kv7.2 
channels showed that the substitution of arginine residue with a tryptophan 
(R6W) or a glutamine (R6Q) did not cause a significant change in maximal 
density of currents when compared to wild type (wt) Kv7.2 channel, thus 
suggesting that plasma-membrane expression of the mutant proteins were not 
affected. Indeed, current densities were 25.9±3.8 pA/pF for wild type subunit, 
24.8±4.5 pA/pF and 33.9±8.1 pA/pF for Kv7.2-R6W and Kv7.2-R6Q, respectively. 
By contrast, both mutations caused a significant decrease in the voltage 
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sensitivity of the channel, with R6Q substitution showing a higher reduction 
compared to R6W. The half activation potential (V1/2) was −23 mV in KV7.2 
channels; this value was right-shifted by 58 mV and 68 mV in R6W and R6Q 
mutant channels, respectively (Fig21). 
 
 
Figure 21. (A) Macroscopic currents from KV7.2, KV7.2 R6W, and KV7.2 R6Q channels, in 
response to the indicated voltage protocols. Current scale, 100 pA; time scale, 0.1 s. The arrows 
indicate the threshold voltage for current activation. (B) Conductance/ voltage curves. 
Continuous lines are Boltzmann fits to the experimental data. 
 
 Since in neuronal cells M current is underlied by homo- or hetero- meric 
assembly of Kv7.2 and Kv7.3 subunits, we investigated the functional 
consequence of the incorporation of mutated proteins in the tetrameric channel. 
Moreover, to reproduce the genetic balance of the patients affected (who are 
heterozygous for the mutant allele) and normal individuals, we transfected CHO 
cells with Kv7.2 and Kv7.3 plasmids in different ratios; in particular, we used wt 
Kv7.2 and Kv7.3 in a 1:1 ratio to reproduce the phenotype of normal individuals, 
and wt Kv7.2+Kv7.2R6W+Kv7.3 or wt Kv7.2+Kv7.2 R6Q+Kv7.3 (0.5:0.5:1 ratio) to 
mimic the genetic balance of affected patients (Fig22).   
Heteromeric channels composed by Kv7.2 and Kv7.3 subunits show larger 
current compared to homomeric tetramers. As for mutated channels in 
homomeric conformation, heteromeric channels formed by Kv7.2R6W or 
Kv7.2R6Q did not display a decrease in macroscopic currents with respect to wt 
Kv7.2, suggesting that they did not interfere with heteromeric assembly and/or 
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trafficking to the plasma membrane (current densities were 110.8±20.7 pA/pF 
for Kv7.2+Kv7.3; 98.8±12.5 pA/pF for Kv7.2+Kv7.2R6W+Kv7.3; and 85.0±17.9 
pA/pF for Kv7.2+Kv7.2R6Q+Kv7.3) (Fig22A). Moreover, a right-shift in the 
voltage dependence of channels incorporating mutated subunit was observed, 
with R6Q showing a more dramatic effect when compared to R6W (V1/2 were 
−30.7±1.4 for Kv7.2+Kv7.3; −22.2±2.0 for Kv7.2+Kv7.2R6W+Kv7.3; −14.7±2.6 for 
Kv7.2+Kv7.2R6Q+Kv7.3). Such a decreased voltage sensitivity determined by the 
arginine substitutions was also evident in Kv7.2 channels in homomeric 
conformation, a channel composition that has been demonstrated to occur at 
specific neuronal sites and during early stages of development. Indeed, 
transfection of CHO cells with wt and mutated Kv7.2 subunit in 1:1 ratio caused 
a right shift in voltage-sensitivity of R6W and R6Q Kv7.2 channels when 
compared to channels composed by wt Kv7.2 (V1/2 were −22.9±1.8 for wild-type 
channels; −6.8±3.1 for Kv7.2wt+Kv7.2R6W; 17.7±3.3 for Kv7.2wt+Kv7.2R6Q) 
(Fig 22B and C). 
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Figure 22. (A) Macroscopic current traces from the indicated heteromeric channels in response 
to the indicated voltage protocols. Current scale, 200 pA; time scale, 0.1 s Arrows indicate the 
threshold voltage for current activation. (B and C) Conductance/voltage curves for the 
heteromeric channels formed by mutant subunits with wild type KV7.2 and KV7.3 (B) or with 
wild type KV7.2 (C). Continuous lines are Boltzmann fits to the experimental data.  
 
To assess the possible effects of the changes in the properties of heteromeric 
Kv7.2 channels induced by R6 aminoacid changes, we introduced the biophysical 
parameters derived from patch-clamp experiments in a model CA1 hippocampal 
neuron.  In this model we evaluated the changes in neuron excitability 
prompted by mutations by measuring the voltage responses and the number of 
action potentials generated in response to a wide range of injected current 
(between 0.3 and 0.7 nA). While CA1 neuron incorporating R6W showed only a 
slightly increase in the number of spikes after current with respect to wt, 
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mutant R6Q CA1 neuron responded with a higher number of spikes when 
compared to wt (Fig23A). Moreover, a higher number of action potential was 
observed for R6Q mutation also at relatively low current injection values, while, 
channels incorporating Kv7.2-R6W subunit caused similar effects only for larger 
input currents (Fig23B). 
 
Figure 23. Modeling of the effects of the KV7.2 R213W (R6W) and R213Q (R6Q) mutations on 
neuronal excitability. (A) Time courses of the somatic membrane potential from CA1 neurons 
expressing KV7.2+KV7.3 (black lines), KV7.2+KV7.2 R6W+KV7.3 (red lines), or KV7.2+KV7.2 
R6Q+KV7.3 (blue lines) heteromeric channels, during a 500-ms somatic current injection of 0.65 
nA. (B) Input/output (I/O) curves from cells expressing KV7.2+KV7.3 (black line), KV7.2+KV7.2 
R6W+KV7.3 (red line), or KV7.2+KV7.2 R6Q+KV7.3 (blue line) heteromeric channels. Number of 
APs (AP#) is expressed as a function of the somatic current injected, using a 120 mS/μm2 peak 
IKM conductance. 
 
We then investigated if the functional changes determined by mutation in R6 
residue could be rescued by retigabine, a Kv7 activator able to increase M 
current (among other mechanisms) also by causing a left-shift in channel 
voltage sensitivity. Retigabine used at the concentration of 1M was able to fully 
reverse the effects on channel gating induced by mutations, thus bringing the 
voltage sensitivity of mutated channels to that of wild type (Fig24). 
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Figure 24. Effect of retigabine on heteromeric KV7.2+KV7.3, KV7.2+KV7.2 R6W+KV7.3, or  
KV7.2+KV7.2 R6Q+KV7.3 channels. (A) Current responses from the indicated heteromeric 
channels to voltage ramps from −80 to 0 mV. C, control currents; RET, retigabine; W, washout. 
Current scale, 200 pA; time scale, 0.2 s. (B) Quantification of the effects of RET on the indicated 
heteromeric channels. Data are expressed as membrane potentials at which currents reached 
20% of their peak value for controls (black bars) and after RET exposure (white bars). *P < 0.05 
vs. corresponding controls; ns, not significantly different). Current scale, 200 pA; time scale, 200 
ms. 
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DISCUSSION 
Ionic homeostasis is a primary goal for excitable cells as neurons, as alterations 
of the concentrations of different ionic species is both a cause and a 
consequence of different pathological processes (apoptosis, cell shrinkage, 
proteases activation) and diseases. In particular, K+ ions imbalance seems to be 
strictly linked to neuronal dysfunction, also for the pivotal role exerted in 
determining resting potential and cell excitability. Indeed, hyper-excitability is a 
common feature of many diseases such as epilepsy and ischemia; as a 
consequence, K+ channels are important regulators of neuronal activity and 
their modulation might have important consequences on neurons 
death/survival. Among them, voltage-gated K+ channels belonging to Kv7 family 
have gained increasing interest since mutations in genes encoding for Kv7.2 and 
Kv7.3 subunits were discovered to cause an inherited form of epilepsy called 
BFNS (Singh et al, 1998; Charlier et al, 1998; Bievert et al, 1998). Subsequently, 
the physiological relevance of Kv7 channels and M-current has been better 
defined, with several studies demonstrating its role in neuronal excitability 
regulation at somato-dendritic, nodal and pre-synaptic levels, thus modulating 
different processes such as neurotransmitters release. Massive 
neurotransmitters release occurs during brain ischemia, possibly due to 
damage-induced depolarisation and/or rising of intracellular Ca2+ 
concentrations (Doyle et al., 2008). In particular, dopamine release has been 
demonstrated to reach very high levels soon after an ischemic insult and also to 
contribute to neuronal damage. Given the known effect of Kv7 activator 
retigabine in reducing dopamine release in isolated nerve terminals (Martire et 
al., 2007), in this study we investigated the possibility that pharmacological 
activation of Kv7-mediated currents could exert neuroprotective effects in a in 
vitro model of ischemia. In particular, we focused on striatum, a region 
receiving dopaminergic projections from mesencephalic substantia nigra, and 
frequently damaged in ischemic stroke in humans (for the occlusion of the 
middle cerebral artery).  
In our experiments retigabine was able to reduce dopamine release induced by 
exposure of striatal brain slices to aCSF deprived of glucose and oxygen; 
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moreover, retigabine also delayed dopamine time to onset and slowed down the 
release. This is particularly relevant, since previous studies have shown that 
putative neuroprotective agents increased time to onset in rat brain slices, thus 
suggesting that delay in this parameter is a good indicator of neuroprotection 
(Toner et al., 2001). Moreover, retigabine exerted its action at the concentration 
(1M) that is very close to the EC50 for the activation of Kv7.2/Kv7.3 heteromers, 
which are thought to be the most frequent channels composition underlying M-
current in brain (Cooper et al., 2000). Neuroprotective actions of retigabine 
were also confirmed by TTC staining experiments, in which neuronal damage 
has been measured by evaluating the mitochondrial dysfunction induced by 
OGD insult. Retigabine dose-dependently reduced brain damage induced by 
OGD, showing a considerable effect also at the concentration of 1M. The 
potential neuroprotective effects of Kv7 channels activation was also confirmed 
by the results obtained using ICA27243, a compound provided with higher 
subunit selectivity, showing a higher potency on Kv7.2/Kv7.3 heterotetramers. 
Although time to onset was not delayed, ICA27243 1M did significantly reduce 
dopamine levels reached after OGD insult, thus possibly preventing the 
detrimental consequences of such a huge release. Indeed, exposure of brain 
slices to different concentrations of ICA27243 reduced brain damage measured 
by TTC staining, with an effect quantitatively similar to that determined by 
retigabine. By contrast, NS15370 1M was not able to reproduce the same 
effects on dopamine release obtained with retigabine and ICA27243, which is 
apparently contradicting. However, it should be mentioned that NS15370, 
although more potent than retigabine, has a very complex effect, showing also 
Kv7 channel blockade at depolarized potential (Dalby-Brown et al., 2013), a 
characteristic that might in part explain the lack of effects in dopamine release 
modulation. Consistent with the previous observations, pharmacological 
blockade of Kv7 channel by linopiridine 10M increased and hastened 
dopamine release; this result was paralleled, at least in part, by the worsening of 
OGD-induced brain damage caused by exposure to linopirine, although at higher 
concentration (30M) than those able to increase dopamine release. Moreover, 
linopiridine 10M was able to reverse the changes in dopamine release induced 
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by retigabine, as well as the reduction in TTC staining loss induced by the Kv7 
activator. Linopiridine-induced increase of dopamine release was not 
completely reproduced by its analogue XE-991 (10M), since the latter caused 
only a slight increase in dopamine peak and in rate of change, without being 
significantly different. Interestingly, XE-991 has been demonstrated to increase 
depolarization-induced dopamine release from isolated striatal nerve endings 
(Martire et al., 2007), but showed no or low efficacy in increasing cortical 
aspartate (Luisi et al., 2009) or hippocampal noradrenaline (Martire et al., 
2004) release from synaptosomes. Differences in the experimental models 
(isolated terminals vs brain slices), as well as in drug pharmacological 
properties and doses might explain this discrepancy. 
Moreover, both qPCR and western blot data showed a decrease in Kv7.2 subunit 
expression after OGD insult, both at transcripts and protein levels. This 
reduction seems to affect only Kv7.2, since transcript levels for other Kv7 
subunits are not significantly different from control condition. Although we do 
not know whether this reduction is a possible pathogenetic mechanism or 
merely a consequence of ischemic damage, pharmacological data suggest that 
M-current mediated by Kv7.2 subunit might counteract abnormal changes 
prompted by ischemia and, at least in part, protect from brain damage. 
Moreover, it has been demonstrated that in striatal synaptosomes selective 
Kv7.2 blockade with a subunit-specific antibody was able to completely abolish 
the decrease of dopamine release induced by retigabine (Martire et al., 2007), 
suggesting a primary role of Kv7.2 subunits as molecular determinants of M-
current in this brain area .  
Taken together, these results might suggest a main role for Kv7.2 also in the 
modulation of dopamine release induced by an ischemic insult. Pharmacological 
activation of M-current, possibly by counteracting the depolarization-induced 
release of neurotransmitters following ischemia, as well as by restoring IKM, 
might represent a useful a new strategy for the treatment of brain ischemia.     
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Kv7.2 and encephalophathy   
As stated before, the pathological role of Kv7.2 is highlighted by genetic disease 
associated to mutations affecting its function. Although in most cases alterations 
of Kv7.2 are responsible for BFNS, a dominantly-inherited neonatal epilepsy 
with generally a favorable outcome, novel mutations have been recently 
identified in children with severe forms of epileptic encephalopathies and 
variable psychomotor impairment (Weckhuysen et al., 2012; Saitsu et al., 2012). 
Molecular basis for this phenotypic variability is yet unknown, but it has been 
hypothesized that specific aminoacid substitutions might prompt different 
functional consequences, thus possibly explaining such variability. To further 
investigate this hypotesis, in the present study we have evaluated the molecular 
pathogenesis of channel dysfunction caused by two mutations affecting the fifth 
arginine of KV7.2-VSD, and responsible for epileptic encephalopathy 
(R6Q)(Weckhuysen et al., 2012), or for BFNS (R6W) (Sadewa et al., 2012). 
Macroscopic current analysis in transfected cells revealed that both mutations, 
in homomeric or heteromeric configuration with KV7.2 and/or KV7.3, did not 
modify the maximal current density, suggesting that they did not interfere with 
channel expression to plasma membrane. By contrast, both mutated channels 
showed a remarkable decrease in their voltage sensitivity, with a more dramatic 
effect for R6Q when compared with the R6W mutation. The shift in voltage 
sensitivity was maximal in mutant homomeric configuration (four mutant 
subunits), intermediate in homomeric configuration with wild type KV7.2 
subunits or in heteromeric configuration with KV7.3 subunits (two mutant 
subunits), and smaller in heteromeric channels reproducing the genetic balance 
of affected individuals (one mutant subunits), thus suggesting that the degree of 
reduction in voltage-sensitivity strongly depended on the number of mutant 
subunit incorporated. The shift in voltage-sensitivity caused by R6W mutation 
was qualitatively and quantitatively similar to that of previously described 
BFNS mutations (Castaldo et al., 2002: Miceli et al., 2009). By contrast, changes 
determined by R6Q subunit, was the most dramatic among the functional 
changes described in KV7.2 channelopathies (Bellini et al., 2010). Such dramatic 
effects were observed both in homomeric conformation with Kv7.2 (a channel 
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composition that has been suggested to occur in key-sites such as Ranvier nodes 
and possibly at pre-synaptic sites), as well as in the heteromeric configuration 
mimicking the genetic balance of the affected individual. Computational results 
from a CA1 model of hippocampal neuron confirmed the higher severity of R6Q 
mutation; indeed, although both mutations increased neuronal excitability, 
incorporation of a single R6Q in heteromeric configuration with KV7.2 and KV7.3 
subunits, dramatically increased neuronal firing, with an effect significantly 
higher than that produced by R6W mutation. Interestingly, retigabine, at 
clinically relevant concentrations (Gunthorpe et al., 2012; Hermann et al., 2003), 
was able to restore normal function in both R6Q and R6W channels, by shifting 
voltage-dependence of these channels to values similar to wild-type subunits. 
Collectively, these results suggest that the more severe phenotype associated to 
R6Q mutation might be due to a greater functional impairment on channel 
activity and in particular on gating properties caused by the mutation, thus 
giving a genotype–phenotype correlation in KV7.2-linked channelopathies. 
Moreover, efficacy of retigabine in counteracting the abnormal changes 
prompted by the mutation might also have relevant impact on treatment of this 
disease; this is particularly important in children, in consideration of the fact 
that most first-line drugs given to neonates to treat seizures (usually 
phenobarbital and phenytoin) are effective in less than 50% of cases, and 
concerns about their administration to children has emerged since they have 
been demonstrated to cause widespread neuronal apoptosis when given to 
young rodents (Painter et al., 1999). 
Taken together, these data suggest that Kv7 channels might play a key 
pathogenetic role in regulation of neuronal dysfunction characterized by hyper-
excitability, and in the sequence of events that lead to severe brain damage and 
neurodegeneration, possibly by counteracting neuronal hyper-excitability and 
consequent massive dopamine (and other neurotransmitter) release occurring 
in this pathological condition. Moreover, pharmacological enhancement of M-
current exerts neuroprotective effects in in vitro model of brain ischemia, and 
fully revert the alterations in biophysics propertiers of channels caused by 
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mutations. Thus, pharmacological modulation of Kv7 channels might represent a 
unique tool to counteract hyperexcitability dysfunction.  
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